Swiss medtech company Medartis Holding yesterday revealed plans for an initial public offering on the SIX Swiss Exchange slated for the first half of this year.
The company produces fixation products designed for treating small-bone fractures and osteotomies in the lower and upper extremities and the craniomaxiofacial region. All device production is managed in-house at its facilities in Basel, Sweden.
Medartis was founded in 1997, sells products in 44 different countries including the US, Japan, the UK, France, Germany, Switzerland, Australia and Brazil.
“The planned IPO will mark an important milestone in the development of Medartis and will allow us to take the company to the next level. There are numerous opportunities for us to grow, and the timing is right for us to offer shares and seek a listing, in order to be in a strong position to capture these favorable prospects. I am extremely proud of what Medartis and our employees have achieved since our founding just over 20 years ago. Our focus on providing customers around the world with innovative, high-quality, Swiss-made fixation system solutions, combined with continuous support and education, has been the cornerstone of our success,” founder & board chair Thomas Straumann said in a press release.
Medartis reported sales of $112 million (SFr 105 million) and an operational EBITDA of $20.1 million (SFr 19 million) during last year.
